Nantong Jinghua Pharmaceutical Co Ltd (002349) - Total Assets
Based on the latest financial reports, Nantong Jinghua Pharmaceutical Co Ltd (002349) holds total assets worth CN¥3.49 Billion CNY (≈ $510.38 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nantong Jinghua Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Nantong Jinghua Pharmaceutical Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Nantong Jinghua Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Nantong Jinghua Pharmaceutical Co Ltd's total assets of CN¥3.49 Billion consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 30.7% |
| Accounts Receivable | CN¥417.26 Million | 12.6% |
| Inventory | CN¥270.35 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥60.52 Million | 1.8% |
| Goodwill | CN¥167.94 Million | 5.1% |
Asset Composition Trend (2006–2024)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nantong Jinghua Pharmaceutical Co Ltd (002349) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nantong Jinghua Pharmaceutical Co Ltd's current assets represent 55.9% of total assets in 2024, an increase from 38.3% in 2006.
- Cash Position: Cash and equivalents constituted 30.7% of total assets in 2024, up from 5.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 12.6% of total assets.
Nantong Jinghua Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nantong Jinghua Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Nantong Jinghua Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.23 | 6.77 | 2.69 |
| Quick Ratio | 4.46 | 5.81 | 2.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.58 Billion | CN¥1.77 Billion | CN¥892.17 Million |
Nantong Jinghua Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nantong Jinghua Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | CN¥3.30 Billion |
| Market Capitalization | $912.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nantong Jinghua Pharmaceutical Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nantong Jinghua Pharmaceutical Co Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nantong Jinghua Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total assets of Nantong Jinghua Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.30 Billion ≈ $483.15 Million |
+3.67% |
| 2023-12-31 | CN¥3.19 Billion ≈ $466.07 Million |
+4.71% |
| 2022-12-31 | CN¥3.04 Billion ≈ $445.09 Million |
-4.89% |
| 2021-12-31 | CN¥3.20 Billion ≈ $467.98 Million |
+1.33% |
| 2020-12-31 | CN¥3.16 Billion ≈ $461.83 Million |
+7.30% |
| 2019-12-31 | CN¥2.94 Billion ≈ $430.41 Million |
-13.48% |
| 2018-12-31 | CN¥3.40 Billion ≈ $497.48 Million |
+4.88% |
| 2017-12-31 | CN¥3.24 Billion ≈ $474.35 Million |
+28.10% |
| 2016-12-31 | CN¥2.53 Billion ≈ $370.29 Million |
+0.97% |
| 2015-12-31 | CN¥2.51 Billion ≈ $366.72 Million |
+32.84% |
| 2014-12-31 | CN¥1.89 Billion ≈ $276.06 Million |
+76.18% |
| 2013-12-31 | CN¥1.07 Billion ≈ $156.69 Million |
+11.81% |
| 2012-12-31 | CN¥957.71 Million ≈ $140.14 Million |
+22.70% |
| 2011-12-31 | CN¥780.53 Million ≈ $114.22 Million |
+27.66% |
| 2010-12-31 | CN¥611.41 Million ≈ $89.47 Million |
+177.45% |
| 2009-12-31 | CN¥220.37 Million ≈ $32.25 Million |
+12.46% |
| 2008-12-31 | CN¥195.95 Million ≈ $28.67 Million |
-2.08% |
| 2007-12-31 | CN¥200.11 Million ≈ $29.28 Million |
+0.97% |
| 2006-12-31 | CN¥198.19 Million ≈ $29.00 Million |
-- |
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and… Read more